Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts
- 1 September 2001
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 10 (9) , 1745-1753
Abstract
Immunocompromised hosts are at increased risk of cytomegalovirus (CMV) infection and serious CMV disease. CMV infection is an important cause of morbidity among patients infected with HIV and after solid organ transplantation (SOT) and may cause life-threatening disease in allogeneic stem cell transplant (SCT) recipients. The introduction into clinical use of potent antiviral compounds and of rapid detection assays for CMV during the past two decades has allowed development of strategies for the prevention and treatment of disease caused by CMV in these groups of immunocompromised patients. At present, the antiviral drugs ganciclovir, foscarnet and cidofovir are commonly used in the treatment of CMV infection and disease. However, these agents have a poor oral bioavailability and, for systemic use, require iv. administration for most indications. Valganciclovir is an oral prodrug of ganciclovir, with a 10-fold greater bioavailability than oral ganciclovir. Studies of the pharmacokinetics of valganciclovir...Keywords
This publication has 52 references indexed in Scilit:
- Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipientsBlood, 2001
- Single‐Dose Pharmacokinetics of Valganciclovir in HIV‐ and CMV‐Seropositive SubjectsThe Journal of Clinical Pharmacology, 1999
- Cytomegalovirus (CMV)–Specific T Cell Immunity after Renal Transplantation Mediates Protection from CMV Disease by Limiting the Systemic Virus LoadThe Journal of Infectious Diseases, 1999
- Recent Advances in Varicella-Zoster Virus InfectionAnnals of Internal Medicine, 1999
- A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989Bone Marrow Transplantation, 1998
- Cytomegalovirus-Specific T-Cell Immunity in Recipients of Autologous Peripheral Blood Stem Cell or Bone Marrow TransplantsBlood, 1997
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Epstein-Barr Virus Infections: Biology, Pathogenesis, and ManagementAnnals of Internal Medicine, 1993
- Cytomegalovirus Infection in Patients with AIDSClinical Infectious Diseases, 1992
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986